Key facts
- This page summarizes Charles S. Berkman's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Nov 2022, 21:06.
Charles S. Berkman - 01 Nov 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)
- Reporting relationship
- Former Executive Officer
- Issuer ticker
- LGND
- Reported as of
- 01 Nov 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Nov 2022, 21:06:31 UTC
- Prior SEC filing
- 30 Sep 2022
- Next SEC filing
- 05 Dec 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Charles S. Berkman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Charles S. Berkman filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 03 Nov 2022.
Change
- Previous filing in this sequence was filed on 30 Sep 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LGND
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -11,944
- Change %
- -33%
- Price
- Shares after
- 23,825
- Date
- 01 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LGND
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -20,126
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 01 Nov 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,126
- Exercise price
- $90.68
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Charles S. Berkman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
Footnote F2
The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.